On January 9, Glorix reported that Novo-Nordisk A/S and the USA technology company Valo Health agreed to expand their collaboration agreement to develop up to 11 drugs in 2023, utilizing human data and AI to develop up to 20 new therapies targeting obesity, type 2 diabetes, and cardiovascular diseases. According to the terms of the extended agreement, Valo is entitled to receive a total of up to $0.19 billion in short-term payments and about $4.6 billion in development milestone payments.
诺和诺德与Valo Health扩大合作 利用人工智能开发减肥药
Novo-Nordisk A/S expands its cooperation with Valo Health to develop weight loss medications using AI.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha